Symbols / TELO Stock $1.29 -0.77% Telomir Pharmaceuticals, Inc.
TELO (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteTelomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Ratings
- Telomir Pharmaceuticals (TELO) director resets 25K stock options terms - Stock Titan Sat, 23 May 2026 00
- Telomir Pharmaceuticals (TELO) director swaps 25K options for lower $1.30 strike - Stock Titan Sat, 23 May 2026 00
- Telomir (TELO) director swaps 25K options for new lower-priced grant - Stock Titan Sat, 23 May 2026 00
- Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - ACCESS Newswire Fri, 24 Apr 2026 07
- Telomir Sets Vote on Transformative TELI Merger and Governance Changes - TipRanks hu, 19 Feb 2026 08
- Will Telomir Pharmaceuticals Bounce Back? - StocksToTrade Fri, 21 Nov 2025 08
- Telomir (NASDAQ: TELO) CEO reshapes 4M+ options at lower $1.30 strike - Stock Titan Sat, 23 May 2026 00
- Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer - ACCESS Newswire ue, 31 Mar 2026 12
- Study links Telomir-Zn to better survival in toxic copper buildup disorder - Stock Titan Wed, 20 May 2026 12
- Wilson’s disease study backs Telomir-Zn for Telomir (NASDAQ: TELO) - Stock Titan Wed, 20 May 2026 12
- Telomir locks up worldwide rights to its lead drug, with $1M now and $4M tied to milestones - Stock Titan Fri, 24 Apr 2026 07
- FDA IND clearance puts Telomir's TNBC drug into first human testing - Stock Titan hu, 30 Apr 2026 07
- Telomir (NASDAQ: TELO) closes TELI deal amid Q1 loss and cash risk - Stock Titan hu, 14 May 2026 07
- Telomir takes experimental TNBC therapy to FDA for metastatic disease - Stock Titan ue, 31 Mar 2026 07
- Telomir Pharmaceuticals (NASDAQ: TELO) clears Teli deal and expands equity incentive plan - Stock Titan Fri, 27 Mar 2026 07
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
10.54
-13.91%
|
12.24
+210.55%
|
3.94
+361.52%
|
0.85
|
| Research And Development |
|
2.44
+8.96%
|
2.24
+41.99%
|
1.57
+88.95%
|
0.83
|
| Selling General And Administration |
|
8.10
-15.91%
|
9.64
+1505.54%
|
0.60
+2766.11%
|
0.02
|
| General And Administrative Expense |
|
8.10
-15.91%
|
9.64
+1505.54%
|
0.60
+2766.11%
|
0.02
|
| Other Gand A |
|
8.10
-15.91%
|
9.64
+1505.54%
|
0.60
+2766.11%
|
0.02
|
| Other Operating Expenses |
|
—
|
0.37
-79.04%
|
1.77
|
—
|
| Total Expenses |
|
10.54
-13.91%
|
12.24
+210.55%
|
3.94
+361.52%
|
0.85
|
| Operating Income |
|
-10.54
+13.91%
|
-12.24
-210.55%
|
-3.94
-361.52%
|
-0.85
|
| EBITDA |
|
-10.41
+14.61%
|
-12.19
-6.70%
|
-11.43
-1238.04%
|
-0.85
|
| Normalized EBITDA |
|
-10.41
+14.61%
|
-12.19
-209.34%
|
-3.94
-361.52%
|
-0.85
|
| EBIT |
|
-10.41
+14.61%
|
-12.19
-6.70%
|
-11.43
-1238.04%
|
-0.85
|
| Total Unusual Items |
|
—
|
0.00
+100.00%
|
-7.49
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
0.00
+100.00%
|
-7.49
|
0.00
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-7.49
|
0.00
|
| Other Special Charges |
|
—
|
—
|
7.49
|
—
|
| Net Income |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Pretax Income |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Net Non Operating Interest Income Expense |
|
0.13
+102.93%
|
-4.29
-161.13%
|
-1.64
|
0.00
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
4.34
+164.05%
|
1.64
|
0.00
|
| Net Interest Income |
|
0.13
+102.93%
|
-4.29
-161.13%
|
-1.64
|
0.00
|
| Interest Expense |
|
0.00
-100.00%
|
4.34
+164.05%
|
1.64
|
0.00
|
| Interest Income Non Operating |
|
0.13
+161.76%
|
0.05
|
0.00
|
—
|
| Interest Income |
|
0.13
+161.76%
|
0.05
|
0.00
|
—
|
| Other Income Expense |
|
—
|
—
|
-7.49
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Net Income From Continuing Operation Net Minority Interest |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Net Income From Continuing And Discontinued Operation |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Net Income Continuous Operations |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Normalized Income |
|
-10.41
+37.01%
|
-16.53
-196.01%
|
-5.59
-553.88%
|
-0.85
|
| Net Income Common Stockholders |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Diluted EPS |
|
—
|
-0.56
-26.85%
|
-0.44
-1430.39%
|
-0.03
|
| Basic EPS |
|
—
|
-0.56
-26.85%
|
-0.44
-1430.39%
|
-0.03
|
| Basic Average Shares |
|
—
|
29.54
-0.24%
|
29.61
+0.00%
|
29.61
|
| Diluted Average Shares |
|
—
|
29.54
-0.24%
|
29.61
+0.00%
|
29.61
|
| Diluted NI Availto Com Stockholders |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
7.34
+454.48%
|
1.32
-72.26%
|
4.77
+9696.36%
|
0.05
|
| Current Assets |
|
7.34
+454.48%
|
1.32
+204.21%
|
0.44
+793.14%
|
0.05
|
| Cash Cash Equivalents And Short Term Investments |
|
7.29
+475.51%
|
1.27
+102753.86%
|
0.00
-13.25%
|
0.00
|
| Cash And Cash Equivalents |
|
7.29
+475.51%
|
1.27
+102753.86%
|
0.00
-13.25%
|
0.00
|
| Cash Financial |
|
7.29
+475.51%
|
1.27
+102753.86%
|
0.00
-13.25%
|
0.00
|
| Receivables |
|
—
|
0.00
-100.00%
|
0.13
|
0.00
|
| Prepaid Assets |
|
0.05
-5.50%
|
0.06
+8016.97%
|
0.00
|
0.00
|
| Current Deferred Assets |
|
—
|
0.00
-100.00%
|
0.30
+541.04%
|
0.05
|
| Total Non Current Assets |
|
0.00
|
0.00
-100.00%
|
4.34
|
0.00
|
| Non Current Deferred Assets |
|
—
|
0.00
-100.00%
|
4.34
|
0.00
|
| Total Liabilities Net Minority Interest |
|
1.43
+109.70%
|
0.68
-49.01%
|
1.34
+35.45%
|
0.99
|
| Current Liabilities |
|
1.43
+109.70%
|
0.68
-49.01%
|
1.34
+35.45%
|
0.99
|
| Payables And Accrued Expenses |
|
1.43
+109.70%
|
0.68
-44.84%
|
1.23
+25.21%
|
0.99
|
| Payables |
|
1.01
+48.39%
|
0.68
-44.84%
|
1.23
+25.21%
|
0.99
|
| Accounts Payable |
|
0.54
-8.64%
|
0.59
-16.92%
|
0.71
+74.95%
|
0.40
|
| Current Accrued Expenses |
|
0.42
|
0.00
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
0.10
|
—
|
| Current Debt |
|
—
|
—
|
0.10
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
5.91
+819.60%
|
0.64
-81.30%
|
3.44
+466.83%
|
-0.94
|
| Common Stock Equity |
|
5.91
+819.60%
|
0.64
-81.30%
|
3.44
+466.83%
|
-0.94
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
34.38
+15.52%
|
29.76
+0.52%
|
29.61
+0.00%
|
29.61
|
| Ordinary Shares Number |
|
34.38
+15.52%
|
29.76
+0.52%
|
29.61
+0.00%
|
29.61
|
| Additional Paid In Capital |
|
46.92
+50.20%
|
31.24
+78.49%
|
17.50
+31722.45%
|
0.06
|
| Retained Earnings |
|
-41.01
-34.03%
|
-30.60
-117.55%
|
-14.06
-1317.36%
|
-0.99
|
| Total Equity Gross Minority Interest |
|
5.91
+819.60%
|
0.64
-81.30%
|
3.44
+466.83%
|
-0.94
|
| Total Capitalization |
|
5.91
+819.60%
|
0.64
-81.30%
|
3.44
+466.83%
|
-0.94
|
| Working Capital |
|
5.91
+819.60%
|
0.64
+171.42%
|
-0.90
+3.94%
|
-0.94
|
| Invested Capital |
|
5.91
+819.60%
|
0.64
-81.83%
|
3.54
+477.60%
|
-0.94
|
| Total Debt |
|
—
|
—
|
0.10
|
—
|
| Net Debt |
|
—
|
—
|
0.10
|
—
|
| Net Tangible Assets |
|
5.91
+819.60%
|
0.64
-81.30%
|
3.44
+466.83%
|
-0.94
|
| Tangible Book Value |
|
5.91
+819.60%
|
0.64
-81.30%
|
3.44
+466.83%
|
-0.94
|
| Duefrom Related Parties Current |
|
—
|
0.00
-100.00%
|
0.13
|
0.00
|
| Dueto Related Parties Current |
|
0.47
+407.06%
|
0.09
-82.28%
|
0.53
-9.35%
|
0.58
|
| Line Of Credit |
|
—
|
0.00
-100.00%
|
0.10
|
0.00
|
| Other Equity Interest |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-3.69
+27.26%
|
-5.07
-31.37%
|
-3.86
-723.58%
|
-0.47
|
| Cash Flow From Continuing Operating Activities |
|
-3.69
+27.26%
|
-5.07
-31.37%
|
-3.86
-723.58%
|
-0.47
|
| Net Income From Continuing Operations |
|
-10.41
+37.01%
|
-16.53
-26.48%
|
-13.07
-1430.40%
|
-0.85
|
| Other Non Cash Items |
|
—
|
4.47
+177.30%
|
1.61
|
—
|
| Stock Based Compensation |
|
6.13
-10.73%
|
6.87
|
0.00
|
—
|
| Operating Gains Losses |
|
—
|
—
|
7.49
|
—
|
| Change In Working Capital |
|
0.59
+370.22%
|
0.13
+11.09%
|
0.11
-70.47%
|
0.39
|
| Change In Prepaid Assets |
|
0.00
+105.57%
|
-0.06
-7916.83%
|
-0.00
|
0.00
|
| Change In Payables And Accrued Expense |
|
0.37
+99.70%
|
0.18
+60.30%
|
0.11
-70.28%
|
0.39
|
| Change In Other Working Capital |
|
0.22
|
—
|
—
|
—
|
| Financing Cash Flow |
|
9.71
+53.25%
|
6.34
+64.14%
|
3.86
+721.05%
|
0.47
|
| Cash Flow From Continuing Financing Activities |
|
9.71
+53.25%
|
6.34
+64.14%
|
3.86
+721.05%
|
0.47
|
| Net Issuance Payments Of Debt |
|
0.16
+253.98%
|
-0.10
-106.95%
|
1.45
+214.11%
|
0.46
|
| Issuance Of Debt |
|
0.16
|
0.00
-100.00%
|
1.45
+214.11%
|
0.46
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.10
|
0.00
|
—
|
| Short Term Debt Issuance |
|
0.16
|
0.00
-100.00%
|
1.45
+214.11%
|
0.46
|
| Short Term Debt Payments |
|
0.00
+100.00%
|
-0.10
|
0.00
|
—
|
| Net Short Term Debt Issuance |
|
0.16
+253.98%
|
-0.10
-106.95%
|
1.45
+214.11%
|
0.46
|
| Net Common Stock Issuance |
|
9.55
+39.81%
|
6.83
+583.30%
|
1.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.04
|
0.00
|
—
|
| Net Other Financing Charges |
|
—
|
-0.43
-130.84%
|
1.41
+18201.39%
|
0.01
|
| Changes In Cash |
|
6.02
+375.97%
|
1.26
+672919.15%
|
-0.00
-113.25%
|
0.00
|
| Beginning Cash Position |
|
1.27
+102753.86%
|
0.00
-13.25%
|
0.00
|
0.00
|
| End Cash Position |
|
7.29
+475.51%
|
1.27
+102753.86%
|
0.00
-13.25%
|
0.00
|
| Free Cash Flow |
|
-3.69
+27.26%
|
-5.07
-31.37%
|
-3.86
-723.58%
|
-0.47
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
—
|
| Common Stock Issuance |
|
9.55
+39.81%
|
6.83
+583.30%
|
1.00
|
0.00
|
| Issuance Of Capital Stock |
|
9.55
+39.81%
|
6.83
+583.30%
|
1.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-05-22 View
- 42026-05-22 View
- 42026-05-22 View
- 42026-05-22 View
- 8-K2026-05-20 View
- 10-Q2026-05-14 View
- 8-K2026-04-30 View
- 42026-04-24 View
- 8-K2026-04-24 View
- 8-K2026-03-31 View
- 8-K2026-03-31 View
- 8-K2026-03-27 View
- 10-K2026-03-17 View
- 8-K2026-02-17 View
- 8-K2026-02-05 View
- 8-K2026-01-12 View
- 8-K2026-01-05 View
- 8-K2025-12-22 View
- 8-K2025-12-17 View
- 8-K2025-11-24 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|